SLDB

SEC source: 0001209191-22-005695 · doc4.xml · derivative · entry 2

Schneider Joel Solomon Zev · CIK 0001727649 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock.

F3 · derivative.exercise_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above.

F3 · derivative.expiration_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above.

SEC source: 0001209191-22-005695 · doc4.xml · derivative · entry 1

Schneider Joel Solomon Zev · CIK 0001727649 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 180,000

Underlying: Common Stock · 180,000 shares

Expires 2032-01-27

F1 · derivative.exercise_date: This option was granted on January 27, 2022 and vests in four equal annual installments on the anniversary of the grant date.

SEC source: 0001209191-22-005683 · doc4.xml · derivative · entry 3

Brennan Erin Powers · CIK 0001764644 · Chief Legal Officer, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,250

Underlying: Common Stock · 81,250 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock.

F4 · derivative.exercise_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above.

F4 · derivative.expiration_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above.

SEC source: 0001209191-22-005683 · doc4.xml · derivative · entry 2

Brennan Erin Powers · CIK 0001764644 · Chief Legal Officer, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,000

Underlying: Common Stock · 63,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock.

F3 · derivative.exercise_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above.

F3 · derivative.expiration_date: The restricted stock units were granted on January 27, 2022 and vest on the same schedule as set forth in footnote (1) above.

SEC source: 0001209191-22-005683 · doc4.xml · derivative · entry 1

Brennan Erin Powers · CIK 0001764644 · Chief Legal Officer, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,000

Underlying: Common Stock · 127,000 shares

Expires 2032-01-27

F1 · derivative.exercise_date: This option was granted on January 27, 2022 and vests in four equal annual installments on the anniversary of the grant date.

SEC source: 0001209191-22-005932 · doc4a.xml · derivative · entry 1

Brennan Erin Powers · CIK 0001764644 · Chief Legal Officer, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,250

Underlying: Common Stock · 81,250 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock.

F2 · derivative.exercise_date: This amendment to the Form 4 filed on January 31, 2022 (the "Original Form 4") is being filed to correct the vesting information on a transaction reported on the Original Form 4. The restricted stock units were granted on January 27, 2022 and vest on the second anniversary of the grant date.

F2 · derivative.expiration_date: This amendment to the Form 4 filed on January 31, 2022 (the "Original Form 4") is being filed to correct the vesting information on a transaction reported on the Original Form 4. The restricted stock units were granted on January 27, 2022 and vest on the second anniversary of the grant date.

SEC source: 0001209191-22-001816 · doc4.xml · derivative · entry 2

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,250

Underlying: Common Stock · 97,250 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuers common stock.

F3 · derivative.exercise_date: The restricted stock units were granted on January 3, 2022 and vest on the same schedule as set forth in footnote (1) above.

F3 · derivative.expiration_date: The restricted stock units were granted on January 3, 2022 and vest on the same schedule as set forth in footnote (1) above.

SEC source: 0001209191-22-001816 · doc4.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,500

Underlying: Common Stock · 194,500 shares

Expires 2032-01-03

F1 · derivative.exercise_date: This option was granted on January 3, 2022 pursuant to a services agreement between the reporting person and the Issuer and will vest in equal quarterly installments beginning three months from the date of the grant, with the final installment vesting 12 months from the date of the grant, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the option will accelerate in full.

SEC source: 0001209191-21-041936 · doc4.xml · derivative · entry 1

Huffines Robert Luther · CIK 0001728221 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-06-16

F1 · derivative.exercise_date: This option was granted on June 16, 2021 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0000899243-21-025027 · doc4.xml · derivative · entry 1

Koppel Adam · CIK 0001578965 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-06-16

F1 · derivative.exercise_date: This option was granted on June 16, 2021 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001209191-21-041939 · doc4.xml · derivative · entry 1

Sullivan Lynne Marie · CIK 0001727640 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-06-16

F1 · derivative.exercise_date: This option was granted on June 16, 2021 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001209191-21-041938 · doc4.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-06-16

F1 · derivative.exercise_date: This option was granted on June 16, 2021 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001209191-21-041935 · doc4.xml · derivative · entry 1

Freed Martin I · CIK 0001676653 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-06-16

F1 · derivative.exercise_date: This option was granted on June 16, 2021 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001209191-21-041934 · doc4.xml · derivative · entry 1

Nagendran Sukumar · CIK 0001665124 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-06-16

F1 · derivative.exercise_date: This option was granted on June 16, 2021 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

SEC source: 0001209191-21-041937 · doc4.xml · derivative · entry 1

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-06-16

F1 · derivative.exercise_date: This option was granted on June 16, 2021 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

SEC source: 0001209191-21-029114 · doc4.xml · derivative · entry 1

Freed Martin I · CIK 0001676653 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2031-04-27

F1 · derivative.exercise_date: This option was granted on April 27, 2021 and will vest in equal quarterly installments over the 12 month period following the grant date, subject to the continued service as a director or consultant.

SEC source: 0001104659-21-046607 · tm2112163-6_4seq1.xml · nonDerivative · entry 2

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 11,580,287

F2 · kind: Acquired pursuant to the Reorganization.

F2 · price: Acquired pursuant to the Reorganization.

F3 · ownership.nature: Held directly by the Fund.

F4 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001104659-21-046607 · tm2112163-6_4seq1.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 787,586

F1 · kind: On April 1, 2021, RA Capital Healthcare Fund, L.P. (the "Fund") acquired a participation interest in the reported shares as part of a reorganization of the assets of a separately managed account (the "Reorganization"). The Fund disclaims beneficial ownership of the reported shares, except to the extent of its pecuniary interest therein.

F1 · price: On April 1, 2021, RA Capital Healthcare Fund, L.P. (the "Fund") acquired a participation interest in the reported shares as part of a reorganization of the assets of a separately managed account (the "Reorganization"). The Fund disclaims beneficial ownership of the reported shares, except to the extent of its pecuniary interest therein.

F1 · ownership.nature: On April 1, 2021, RA Capital Healthcare Fund, L.P. (the "Fund") acquired a participation interest in the reported shares as part of a reorganization of the assets of a separately managed account (the "Reorganization"). The Fund disclaims beneficial ownership of the reported shares, except to the extent of its pecuniary interest therein.

F4 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0001062993-21-002952 · form4.xml · nonDerivative · entry 1

PERCEPTIVE ADVISORS LLC · CIK 0001224962 · Director · 10% owner

PERCEPTIVE LIFE SCIENCES MASTER FUND LTD · CIK 0001249675 · Director · 10% owner

EDELMAN JOSEPH · CIK 0001164426 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 13,412,552

F1 · ownership.nature: The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

SEC source: 0000899243-21-013476 · doc4.xml · nonDerivative · entry 1

Koppel Adam · CIK 0001578965 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 7,929,918

F3 · kind: On March 23, 2021, BCLS purchased 869,565 shares of common stock of the Issuer at a price per share of $5.75, pursuant to an underwritten public offering.

F3 · shares: On March 23, 2021, BCLS purchased 869,565 shares of common stock of the Issuer at a price per share of $5.75, pursuant to an underwritten public offering.

F1 · ownership.nature: Represents shares of common stock held directly by BCLS SB Investco, LP ("BCLS").

F2 · ownership.nature: Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of BCLS. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the shares of common stock held by BCLS. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-21-040327 · tm2110617-1_4seq1.xml · nonDerivative · entry 1

RA CAPITAL MANAGEMENT, L.P. · CIK 0001346824 · Director · 10% owner

RA Capital Healthcare Fund LP · CIK 0001315082 · Director · 10% owner

Kolchinsky Peter · CIK 0001384859 · Director · 10% owner

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 10,916,567

F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The securities reported on this Form 4 are held directly by the Fund. Mr. Shah is a member of the board of directors of the Issuer. The filing of this Form 4 shall not be construed as an admission that either the Adviser, the Adviser GP, or Dr. Kolchinsky is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the reported securities, and they disclaim beneficial ownership of any of the reported securities, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-21-020433 · doc4.xml · nonDerivative · entry 2

Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,602

F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1) adopted by the reporting person on May 15, 2020.

SEC source: 0001209191-21-020433 · doc4.xml · nonDerivative · entry 1

Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 287,301

F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1) adopted by the reporting person on May 15, 2020.

SEC source: 0001209191-21-020432 · doc4.xml · nonDerivative · entry 2

Schneider Joel Solomon Zev · CIK 0001727649 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 268,774

F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1) adopted by the reporting person on May 12, 2020.

SEC source: 0001209191-21-020432 · doc4.xml · nonDerivative · entry 1

Schneider Joel Solomon Zev · CIK 0001727649 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 280,473

F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1) adopted by the reporting person on May 12, 2020.

SEC source: 0001209191-21-017948 · doc4.xml · derivative · entry 1

Keresty Georgia · CIK 0001773532 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2031-03-02

F1 · derivative.exercise_date: This option was granted on March 2, 2021 and vests in three equal annual installments on the anniversary of the grant date, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the option will accelerate in full.

SEC source: 0001209191-21-017929 · doc4.xml · derivative · entry 1

Kahn Clare · CIK 0001849236 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2031-03-02

F1 · derivative.exercise_date: This option was granted on March 2, 2021 and vests in three equal annual installments on the anniversary of the grant date, subject to continued service as a director, and in the event of a change in control, the vesting schedule of the option will accelerate in full.

SEC source: 0001209191-21-017903 · doc4.xml · derivative · entry 1

Schneider Joel Solomon Zev · CIK 0001727649 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-03-02

F1 · derivative.exercise_date: This option was granted on March 2, 2021 and vests in four equal annual installments on the anniversary of the grant date.

SEC source: 0001209191-21-016849 · doc4.xml · derivative · entry 1

Brennan Erin Powers · CIK 0001764644 · Chief Legal Officer, Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 325,000

Underlying: Common Stock · 325,000 shares

Expires 2031-03-01

F1 · derivative.exercise_date: This option was granted on March 1, 2021 and vests in four equal annual installments on the anniversary of the grant date.

SEC source: 0001209191-21-010690 · doc4.xml · nonDerivative · entry 1

Ganot Ilan · CIK 0001727460 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Indirect · Wife

Disclosed balance after: 3,026

F1 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units.

SEC source: 0001209191-21-006067 · doc4.xml · nonDerivative · entry 2

Ganot Ilan · CIK 0001727460 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,199,821

F3 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units.

F4 · ownership.direct: Represents 1,139,190 shares held by Mr. Ganot as an individual, and 60,631 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship.

SEC source: 0001209191-21-006068 · doc4.xml · nonDerivative · entry 2

Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 299,000

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units.

SEC source: 0001209191-21-006070 · doc4.xml · nonDerivative · entry 2

Schneider Joel Solomon Zev · CIK 0001727649 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 292,172

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units.

SEC source: 0001209191-21-006069 · doc4.xml · nonDerivative · entry 2

Ziolkowski Jennifer Lynn · CIK 0001727410 · CFO, Treasurer & Asst. Secy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,636

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units.

SEC source: 0001209191-21-006067 · doc4.xml · derivative · entry 5

Ganot Ilan · CIK 0001727460 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted Stock units convert into common stock on a one-for-one basis.

F6 · derivative.exercise_date: On January 27, 2020, the reporting person was granted 71,000 restricted stock units, vesting in two equal installments. Fifty percent vested six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date.

F6 · derivative.expiration_date: On January 27, 2020, the reporting person was granted 71,000 restricted stock units, vesting in two equal installments. Fifty percent vested six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date.

SEC source: 0001209191-21-006067 · doc4.xml · nonDerivative · entry 1

Ganot Ilan · CIK 0001727460 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,210,534

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted Stock units convert into common stock on a one-for-one basis.

F2 · ownership.direct: Represents 1,149,903 shares held by Mr. Ganot as an individual, and 60,631 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship.

SEC source: 0001209191-21-006068 · doc4.xml · derivative · entry 3

Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted Stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On January 27, 2020, the reporting person was granted 23,000 restricted stock units, vesting in two equal installments. Fifty percent vested six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date

F3 · derivative.expiration_date: On January 27, 2020, the reporting person was granted 23,000 restricted stock units, vesting in two equal installments. Fifty percent vested six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date

SEC source: 0001209191-21-006068 · doc4.xml · nonDerivative · entry 1

Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 302,459

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted Stock units convert into common stock on a one-for-one basis.

SEC source: 0001209191-21-006070 · doc4.xml · derivative · entry 3

Schneider Joel Solomon Zev · CIK 0001727649 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted Stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On January 27, 2020, the reporting person was granted 23,000 restricted stock units, vesting in two equal installments. Fifty percent vested six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date

F3 · derivative.expiration_date: On January 27, 2020, the reporting person was granted 23,000 restricted stock units, vesting in two equal installments. Fifty percent vested six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date

SEC source: 0001209191-21-006070 · doc4.xml · nonDerivative · entry 1

Schneider Joel Solomon Zev · CIK 0001727649 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 295,615

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted Stock units convert into common stock on a one-for-one basis.

SEC source: 0001209191-21-006069 · doc4.xml · derivative · entry 3

Ziolkowski Jennifer Lynn · CIK 0001727410 · CFO, Treasurer & Asst. Secy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted Stock units convert into common stock on a one-for-one basis.

F3 · derivative.exercise_date: On January 27, 2020, the reporting person was granted 23,000 restricted stock units, vesting in two equal installments. Fifty percent vested six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date.

F3 · derivative.expiration_date: On January 27, 2020, the reporting person was granted 23,000 restricted stock units, vesting in two equal installments. Fifty percent vested six months after the grant date with the remaining fifty percent vesting on the first anniversary of the grant date.

SEC source: 0001209191-21-006069 · doc4.xml · nonDerivative · entry 1

Ziolkowski Jennifer Lynn · CIK 0001727410 · CFO, Treasurer & Asst. Secy

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 339,109

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted Stock units convert into common stock on a one-for-one basis.

SEC source: 0001209191-21-005639 · doc4.xml · derivative · entry 2

Ganot Ilan · CIK 0001727460 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Indirect · Wife

Disclosed balance after: 8,100

Underlying: Common Stock · 8,100 shares

Expires 2031-01-25

F1 · derivative.exercise_date: This option was granted on January 25, 2021 and vests in four equal annual installments on the anniversary of the grant date.

SEC source: 0001209191-21-005639 · doc4.xml · derivative · entry 1

Ganot Ilan · CIK 0001727460 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 438,000

Underlying: Common Stock · 438,000 shares

Expires 2031-01-25

F1 · derivative.exercise_date: This option was granted on January 25, 2021 and vests in four equal annual installments on the anniversary of the grant date.

SEC source: 0001209191-21-005638 · doc4.xml · derivative · entry 1

Morris Carl Ashley · CIK 0001727571 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2031-01-25

F1 · derivative.exercise_date: This option was granted on January 25, 2021 and vests in four equal annual installments on the anniversary of the grant date.

SEC source: 0001209191-21-005640 · doc4.xml · derivative · entry 1

Schneider Joel Solomon Zev · CIK 0001727649 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2031-01-25

F1 · derivative.exercise_date: This option was granted on January 25, 2021 and vests in four equal annual installments on the anniversary of the grant date.

SEC source: 0001209191-21-001966 · doc4.xml · derivative · entry 1

SMITH IAN F · CIK 0001197032 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 389,000

Underlying: Common Stock · 389,000 shares

Expires 2031-01-04

F1 · derivative.exercise_date: This option was granted on January 4, 2021 and will vest in equal quarterly installments beginning three months from the date of the grant with the final installment vesting date being the later of the completion of a specified service requirement under his consulting agreement or 12 months from the date of the grant, subject to continued service as a director or consultant, and in the event of a change in control, the vesting schedule of the option will accelerate in full.

SEC source: 0000899243-20-033569 · doc4.xml · nonDerivative · entry 1

Koppel Adam · CIK 0001578965 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 7,060,353

F3 · kind: On December 10, 2020, BCLS purchased 3,189,189 shares of common stock directly from the Issuer at a price per share of $3.70.

F3 · shares: On December 10, 2020, BCLS purchased 3,189,189 shares of common stock directly from the Issuer at a price per share of $3.70.

F1 · ownership.nature: Represents shares of common stock held directly by BCLS SB Investco, LP ("BCLS").

F2 · ownership.nature: Bain Capital Life Sciences Investors, LLC, whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of BCLS. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the shares of common stock held by BCLS. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-20-063216 · doc4.xml · nonDerivative · entry 1

Ganot Ilan · CIK 0001727460 · Director · CEO & President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,175,034

F1 · ownership.direct: Represents 1,114,403 shares held by Mr. Ganot as an individual. Represents 60,631 shares held by Mr. Ganot and Annie Ganot as joint tenants with a right of survivorship.

SEC source: 0001104659-20-135400 · tm2038490-1_form4.xml · nonDerivative · entry 1

Shah Rajeev M. · CIK 0001619841 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 8,709,882

F1 · balance_after: The securities reported on this Form 4 exclude 799,564 shares held in an account owned by a separately managed account (the "Account") that were reported on the previous Form 4 filed by Mr. Shah. RA Capital Management, L.P. (the "Adviser") is the investment adviser of the Account. The shares held by the Account have been excluded from the securities reported on this Form 4 pursuant to Rule 16a-1(a)(2)(ii)(C).

F2 · ownership.nature: The Adviser is the investment manager for the RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The filing of this Form 4 shall not be construed as an admission that Mr. Shah is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of the reported securities, and he disclaims beneficial ownership of the reported securities except to the extent of any pecuniary interest.